Financial Report: Merck

Merck

3Q Revenues: $10.5 billion (+5%)

3Q Earnings: $2.2 billion (+19%)

YTD Revenues: $29.7 billion (+1%)

YTD Earnings: $4.5 billion (+30%)

Comments: Pharmaceutical sales were up 6% in the quarter to $9.4 billion, reflecting higher vaccines sales, oncology, cardiovascular franchise sales and hospital acute care. Sales of GARDASIL 9 and GARDASIL were up 38% to $860 million and PROQUAD / M-M-R II sales were up 27% to $496 million, driven by the timing of sales activity in the third quarter of 2015 related to the Pediatric Vaccine Stockpile of the U.S. CDC. Zepatier sales were $326 million in the quarter. Growth in oncology was driven by KEYTRUDA, with sales were up 124% to $356 million as new indications were launched globally. Higher sales in the cardiovascular portfolio were driven by ZETIA up 6% to $671 million, helping to offset by lower sale sales of Vytorin, down 10% to $273 million. Remicade sales were down 30% to $311 million. Isentress sales were $372 million, down 1%. Results includes a $117 million gain related to the settlement of certain patent litigation. Other (income) expense in the quarter and first nine months of 2015 includes a $250 million gain on the sale of certain migraine clinical development programs.